Next Phase Newsletter

A long-established venture capital firm based in Asia is affiliated with one of the world’s largest financial services groups. The firm invests across multiple sectors, including life sciences, and has the flexibility to deploy multi-million-dollar investments depending on the opportunity. The firm evaluates opportunities globally and is actively seeking new international investments. 

Within life sciences, the firm focuses on therapeutics and medical technologies that address significant unmet medical needs relevant to the firm’s domestic market. The firm is particularly interested in companies with clear partnership strategies involving pharmaceutical or healthcare organizations, including licensing, co-development, and strategic investment structures. The firm evaluates a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated products. The firm primarily targets programs in Phase I clinical development but may also consider opportunities approaching clinical entry within approximately one year. Areas of interest include oncology, orphan diseases, and other high unmet need indications. 

From an investment structure perspective, the firm prefers to co-invest alongside established institutional investors in opportunities outside its domestic market. As a result, the firm strongly prefers companies with a credible lead investor or an existing institutional syndicate already in place. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.  

The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.  

The firm does not impose strict requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.  

The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.  

From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

 
A large multi-stage venture capital and private equity firm manages substantial assets across multiple strategies. The firm recently established a dedicated life sciences investment vehicle focused on global venture, growth-stage, and co-investment opportunities. The strategy operates in partnership with major international healthcare and investment organizations to support long-term value creation and commercialization.  

The firm invests broadly across life sciences while expanding its focus into digital healthcare and bio-IT convergence. The strongest areas of interest remain within therapeutics, particularly antibody-drug conjugates (ADC), targeted protein degradation (TPD), and cell and gene therapy. Key therapeutic areas include oncology, metabolic disorders, immunology, and neurology. The firm is also actively evaluating opportunities in AI-enabled healthcare, medical data infrastructure, synthetic biology, next-generation diagnostics, and wearable technologies.  

From a company and management team perspective, the firm prioritizes teams with strong scientific and technical expertise. The investment team includes professionals with R&D and clinical development backgrounds who conduct in-depth technical evaluations. Following investment, the firm leverages strategic global partnerships and industry networks to support commercialization, business development, and technology transfer from academic and research institutions. The firm is particularly interested in companies with strong expansion potential or opportunities positioned for strategic or early exit outcomes. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

An early-stage investment and development firm based in the United States operates under an evergreen investment structure. The firm manages substantial long-term capital and maintains flexibility in both investment size and transaction structure. Initial investments typically range from approximately $1M to $10M, with additional reserves available for continued support of successful portfolio companies.  

The firm focuses on medical devices and research tools. Within medical devices, the firm prefers technologies pursuing higher-barrier regulatory pathways, including PMA approvals. Within research tools, the firm invests in technologies that enable or enhance the discovery and manufacturing of therapeutics and diagnostics, particularly those with meaningful commercial scalability and strong recurring revenue potential.  

From a company and management team perspective, the firm seeks to invest in small, early-stage companies led by lean but highly capable management and execution teams. The firm primarily focuses on opportunities in the United States while remaining open to select opportunities in Europe. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology